Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048360 · ClinicalTrials.gov registry record · Phase 3
Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 162
- Enrollment target
NCT00048360 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 162 participants.
The verdict
NCT00048360, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 162 participants
- Enrollment target
Study Summary
This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).
Interventions
- DRUG Extended-release bupropion hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2002-10 |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048360
The ClinicalTrials.gov registry entry for NCT00048360 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Extended-release bupropion hydrochloride is the first listed.
NCT00048360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048360 about?
NCT00048360 is a clinical study titled "Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults". This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).
What is the current status of trial NCT00048360?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 162 participants. The study started on 2002-10. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00048360?
The interventions under investigation include: Extended-release bupropion hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00048360?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.